Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRIDGEBIO PHARMA, INC.

(BBIO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/26/2021 11/29/2021 11/30/2021 12/01/2021 12/02/2021 Date
39.55(c) 38.04(c) 40.5(c) 39.56(c) 39.47 Last
488 526 733 614 1 873 387 1 503 777 295 503 Volume
-2.92% -3.82% +6.47% -2.32% -0.23% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 81,0 M - -
Net income 2021 -534 M - -
Net Debt 2021 371 M - -
P/E ratio 2021 -10,7x
Yield 2021 -
Sales 2022 108 M - -
Net income 2022 -568 M - -
Net Debt 2022 638 M - -
P/E ratio 2022 -10,2x
Yield 2022 -
Capitalization 5 823 M 5 823 M -
EV / Sales 2021 76,5x
EV / Sales 2022 59,9x
Nbr of Employees 391
Free-Float 63,6%
More Financials
Company
BridgeBio Pharma, Inc. is a United States-based company, The Company discovers and develops medicines that target well-characterized genetic diseases. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-561,... 
Sector
Pharmaceuticals
Calendar
03/07Earnings Release
More about the company
Ratings of BridgeBio Pharma, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about BRIDGEBIO PHARMA, INC.
12/01BRIDGEBIO PHARMA : Corporate Presentation December 2021
PU
11/19BridgeBio Pharma, Helsinn Group Team Up to Jointly Develop, Market New Cancer Treatment
MT
11/19SVB Leerink Adjusts BridgeBio Pharma's Price Target to $66 from $68, Keeps Outperform R..
MT
11/19BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and C..
AQ
11/19BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and C..
CI
11/18BRIDGEBIO PHARMA : Secures Up to $750 Million in Non-Dilutive Debt Financing - Form 8-K
PU
11/18BRIDGEBIO PHARMA, INC. : Entry into a Material Definitive Agreement, Termination of a Mate..
AQ
11/18BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing
GL
11/18BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing
GL
11/18BridgeBio Pharma, Inc. Executes Definitive Credit Facility Agreement with Syndicate of ..
CI
11/05BridgeBio Corporate Presentation November 2021
PU
11/04BRIDGEBIO PHARMA, INC. Management's Discussion and Analysis of Financial Condition and..
AQ
11/04BridgeBio Pharma Q3 Net Loss Widens as Revenue Falls
MT
11/04BRIDGEBIO PHARMA : Q3 Earnings Snapshot
AQ
11/04BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update - For..
PU
More news
News in other languages on BRIDGEBIO PHARMA, INC.
11/19BridgeBio Pharma et le groupe Helsinn s'associent pour développer et commercialiser con..
11/04La perte nette de BridgeBio Pharma au troisième trimestre s'accentue en raison de la ba..
11/04Earnings Flash (BBIO) BRIDGEBIO affiche un chiffre d'affaires de 2,3 millions de dollar..
11/03BridgeBio annonce que le premier patient a reçu une dose dans le cadre de l'essai de ph..
10/29BridgeBio Pharma conclut des accords de recherche avec Columbia et l'école de médecine ..
More news
Analyst Recommendations on BRIDGEBIO PHARMA, INC.
More recommendations
Chart BRIDGEBIO PHARMA, INC.
Duration : Period :
BridgeBio Pharma, Inc. Technical Analysis Chart | BBIO | US10806X1028 | MarketScreener
Technical analysis trends BRIDGEBIO PHARMA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 39,56 $
Average target price 81,20 $
Spread / Average Target 105%
EPS Revisions
Managers and Directors
Neil Kumar Chief Executive Officer & Director
Brian C. Stephenson Chief Financial Officer & Secretary
Uma Sinha Chief Scientific Officer
Richard H. Scheller Director, Chairman-Research & Development
Christine E. Siu Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BRIDGEBIO PHARMA, INC.-44.37%5 823
JOHNSON & JOHNSON0.44%416 161
ROCHE HOLDING AG18.38%343 323
PFIZER, INC.48.55%306 912
NOVO NORDISK A/S66.91%247 444
ELI LILLY AND COMPANY47.55%225 859